Sama Therapeutics
Sama Therapeutics provides a platform that develops predictive biomarkers and models to improve neuropsychiatry research and therapeutic development. The company uses AI/ML, generative models, causal inference, and multimodal data (neural, physiological, multi-omics, natural language, and behavioral phenotypes) via its iMAGiNE™ SaaS platform to validate transdiagnostic signals and support precision clinical trials and preclinical translation. Its approach combines proprietary and open-science datasets and supports software-as-a-medical-device applications and neurostimulation and pharmaceutical efficacy analysis. Sama serves pharmaceutical developers, clinical researchers, and neurotechnology partners focused on cognitive, affective, interoceptive, and substance use indications. The platform targets the growing market for precision neuropsychiatry and psychedelic-inspired R&D by enabling data-driven trial design and biomarker-led decision making.
Sama Therapeutics
Sama Therapeutics provides a platform that develops predictive biomarkers and models to improve neuropsychiatry research and therapeutic development. The company uses AI/ML, generative models, causal inference, and multimodal data (neural, physiological, multi-omics, natural language, and behavioral phenotypes) via its iMAGiNE™ SaaS platform to validate transdiagnostic signals and support precision clinical trials and preclinical translation. Its approach combines proprietary and open-science datasets and supports software-as-a-medical-device applications and neurostimulation and pharmaceutical efficacy analysis. Sama serves pharmaceutical developers, clinical researchers, and neurotechnology partners focused on cognitive, affective, interoceptive, and substance use indications. The platform targets the growing market for precision neuropsychiatry and psychedelic-inspired R&D by enabling data-driven trial design and biomarker-led decision making.